Skip to content Skip to sidebar Skip to footer
Página inicial / Jun Wang Icahn School of Medicine at Mount Sinai

Jun Wang Icahn School of Medicine at Mount Sinai

Postar um comentário

Review

. 2020 Apr 14;52(4):583-589.

doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.

SARS-CoV-2 Vaccines: Status Report

Affiliations

  • PMID: 32259480
  • PMCID: PMC7136867
  • DOI: 10.1016/j.immuni.2020.03.007

Free PMC article

Review

SARS-CoV-2 Vaccines: Status Report

Fatima Amanat  et al. Immunity. .

Free PMC article

Abstract

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.

Figures

Figure 1
Figure 1

Overview of Potential SARS-CoV-2 Vaccine Platforms The structure of a coronavirus particle is depicted on the left, with the different viral proteins indicated. The S protein is the major target for vaccine development. The spike structure shown is based on the trimeric SARS-CoV-1 spike (PDB:

5XL3

). One trimer is shown in dark blue, and the receptor binding domain, a main target of neutralizing antibodies, is highlighted in purple. The other two trimers are shown in light blue. SARS-CoV-2 vaccine candidates based on different vaccine platforms have been developed, and for some of them, pre-clinical experiments have been initiated. For one mRNA-based candidate, a clinical trial recently started to enroll volunteers shortly (ClinicalTrials.gov: NCT04283461). However, many additional steps are needed before these vaccines can be used in the population, and this process might take months, if not years. 1For some candidates, cGMP processes have already been established. 2Clinical trial design might be altered to move vaccines through clinical testing quicker.

Similar articles

  • Developing Covid-19 Vaccines at Pandemic Speed.

    Lurie N, Saville M, Hatchett R, Halton J. Lurie N, et al. N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30. N Engl J Med. 2020. PMID: 32227757 No abstract available.

  • COVID-19 Vaccine: A comprehensive status report.

    Kaur SP, Gupta V. Kaur SP, et al. Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13. Virus Res. 2020. PMID: 32800805 Free PMC article. Review.

  • The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

    Frederiksen LSF, Zhang Y, Foged C, Thakur A. Frederiksen LSF, et al. Front Immunol. 2020 Jul 21;11:1817. doi: 10.3389/fimmu.2020.01817. eCollection 2020. Front Immunol. 2020. PMID: 32793245 Free PMC article. Review.

  • Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.

    Kim KD, Hwang I, Ku KB, Lee S, Kim SJ, Kim C. Kim KD, et al. J Microbiol Biotechnol. 2020 Aug 28;30(8):1109-1115. doi: 10.4014/jmb.2006.06006. J Microbiol Biotechnol. 2020. PMID: 32627758 Review.

  • Keeping track of the SARS-CoV-2 vaccine pipeline.

    Parker EPK, Shrotri M, Kampmann B. Parker EPK, et al. Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1. Nat Rev Immunol. 2020. PMID: 32989290 Free PMC article.

Cited by 498 articles

  • Functionalized Nanoparticles in Prevention and Targeted Therapy of Viral Diseases With Neurotropism Properties, Special Insight on COVID-19.

    Ren M, Wang Y, Luo Y, Yao X, Yang Z, Zhang P, Zhao W, Jiang D. Ren M, et al. Front Microbiol. 2021 Nov 15;12:767104. doi: 10.3389/fmicb.2021.767104. eCollection 2021. Front Microbiol. 2021. PMID: 34867899 Free PMC article. Review.

  • Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses.

    Yin V, Lai SH, Caniels TG, Brouwer PJM, Brinkkemper M, Aldon Y, Liu H, Yuan M, Wilson IA, Sanders RW, van Gils MJ, Heck AJR. Yin V, et al. ACS Cent Sci. 2021 Nov 24;7(11):1863-1873. doi: 10.1021/acscentsci.1c00804. Epub 2021 Nov 4. ACS Cent Sci. 2021. PMID: 34845440 Free PMC article.

  • Tracking SARS-CoV-2: Novel Trends and Diagnostic Strategies.

    Guaman-Bautista LP, Moreta-Urbano E, Oña-Arias CG, Torres-Arias M, Kyriakidis NC, Malcı K, Jonguitud-Borrego N, Rios-Solis L, Ramos-Martinez E, López-Cortés A, Barba-Ostria C. Guaman-Bautista LP, et al. Diagnostics (Basel). 2021 Oct 26;11(11):1981. doi: 10.3390/diagnostics11111981. Diagnostics (Basel). 2021. PMID: 34829328 Free PMC article. Review.

  • Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning.

    Park JJ, Chen S. Park JJ, et al. Patterns (N Y). 2021 Nov 18:100407. doi: 10.1016/j.patter.2021.100407. Online ahead of print. Patterns (N Y). 2021. PMID: 34812427 Free PMC article.

  • Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.

    Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Zare H, et al. Int Immunopharmacol. 2021 Dec;101(Pt B):108351. doi: 10.1016/j.intimp.2021.108351. Epub 2021 Nov 10. Int Immunopharmacol. 2021. PMID: 34801416 Free PMC article.

References

    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., Smith E.C., Case J.B., Feng J.Y., Jordan R. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018;9 e00221-18. - PMC - PubMed
    1. Agrawal A.S., Tao X., Algaissi A., Garron T., Narayanan K., Peng B.H., Couch R.B., Tseng C.T. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 2016;12:2351–2356. - PMC - PubMed
    1. Bao L., Deng W., Huang B., Gao H., Ren L., Wei Q., Yu P., Xu Y., Liu J., Qi F. The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice. bioRxiv. 2020 doi: 10.1101/2020.02.07.939389. - DOI
    1. Benoit A., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., McElhaney J.E., Oostvogels L., van Essen G.A., Gaglani M. Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. Open Forum Infect. Dis. 2015;2:ofv067. - PMC - PubMed
    1. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., Baric R.S. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011;85:12201–12215. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

  • Full Text Sources

    • Elsevier Science
    • Europe PubMed Central
    • Ovid Technologies, Inc.
    • PubMed Central

  • Medical

    • Genetic Alliance

  • Miscellaneous

    • NCI CPTAC Assay Portal

Jun Wang Icahn School of Medicine at Mount Sinai

Source: https://pubmed.ncbi.nlm.nih.gov/32259480/

Postar um comentário for "Jun Wang Icahn School of Medicine at Mount Sinai"